Aim: To compare the effectiveness of teneligliptin/ metformin as monotherapies with teneligliptin[1]metformin combination therapies in an Indian setting. Patients and Methods: The prospective observational study included 207 subjects aged >40 years with suboptimal control of T2DM (glycated hemoglobin (HbA1c) >7.5%). The subjects were categorized into the following three groups based on the treatment received: 63 (30.4%) in group 1 received 20 mg of teneligliptin and metformin SR (500 mg) as individual therapies, 76 (36.7%) in group 2 were managed with 1000 mg metformin and 20 mg of teneligliptin in combination, and 68 subjects (32.9%) in group 3 received 500 mg metformin and 20 mg of teneligliptin in combination. HbA1c, FGS, and PPBG were measured for all the participants at baseline and after the administration of drugs (HbA1c at 12 weeks, and FGS and PPBG at 4 and 12 weeks). Anthropometric and laboratory parameters were compared by ANOVA for normal data, Kruskal Wallis for not normal data and chi-square test for counts data. Results: The mean age of patients was 53.94 ± 10.64 years with a male-to-female ratio of 1:0.76. Comparisons of all the variables between baseline and 12th week were found to be highly significant across the three groups and further t-test analysis also corroborated the findings (P<0.001). Percentage changes showed that the overall effects of the drugs in reducing HbA1c, FGS and PPBS were more prominent in the group 3 followed by group 2 > and 1. Conclusion: Combined pill metformin (500 mg)- teneligliptin (20 mg) may serve as effective alternative to metformin/teneligliptin individual therapies, thereby to reduce the pill burden and improve patient compliance in an Indian setting.